Health Impact and Cost-Effectiveness of Implementing Gender-Neutral Vaccination With the 9-Valent Human Papillomavirus Vaccine in Belgium.
Saved in:
| Title: | Health Impact and Cost-Effectiveness of Implementing Gender-Neutral Vaccination With the 9-Valent Human Papillomavirus Vaccine in Belgium. |
|---|---|
| Authors: | Simoens S; KU Leuven Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium., Bento-Abreu A; Merck Sharp & Dohme, Brussels, Belgium., Merckx B; Merck Sharp & Dohme, Brussels, Belgium., Joubert S; Merck Sharp & Dohme, Brussels, Belgium., Vermeersch S; Merck Sharp & Dohme, Brussels, Belgium., Pavelyev A; Merck & Co., Inc., Kenilworth, NJ, United States.; HCL America, Inc., Sunnyvale, CA, United States., Varga S; Merck & Co., Inc., Kenilworth, NJ, United States., Morais E; Merck Sharp & Dohme, Lyon, France. |
| Source: | Frontiers in pharmacology [Front Pharmacol] 2021 Apr 12; Vol. 12, pp. 628434. Date of Electronic Publication: 2021 Apr 12 (Print Publication: 2021). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Media] Country of Publication: Switzerland NLM ID: 101548923 Publication Model: eCollection Cited Medium: Print ISSN: 1663-9812 (Print) Linking ISSN: 16639812 NLM ISO Abbreviation: Front Pharmacol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
